CANTEL MEDICAL REPORTS

EPS OF
$0.12 VS. $0.06 ON 25% INCREASE IN SALES
FOR QUARTER ENDED JULY 31, 2007

LITTLE FALLS,
New Jersey (October 9,
2007) ... CANTEL MEDICAL CORP.
(NYSE:CMN) reported income from continuing operations of $1,899,000, or $0.12
per diluted share, on a 25% increase in sales to $62,513,000 for the fourth
quarter ended July 31, 2007, inclusive of approximately $0.02 in expenses
related to recent acquisitions and executive transition, as well as $0.03
of stock-based compensation. This compares with income from continuing
operations of $922,000, or $0.06 per diluted share, on sales of $50,140,000 for
the fourth quarter ended July 31, 2006, including $0.01 of stock-based
compensation expense.

For the fiscal year ended July
31, 2007, the Company reported income from continuing operations of $8,104,000,
or $0.50 per diluted share, on a 14% increase in sales to $219,044,000,
inclusive of expenses of $0.03 related to recent acquisitions and executive
transition, as well as $0.06 of stock-based compensation. This compares with
income from continuing operations of $6,653,000, or $0.41 per diluted share, on
sales of $192,179,000 for the fiscal year ended July 31, 2006, including $0.05
of stock-based compensation expense.

According to R.
Scott Jones, Cantels President & CEO, We are pleased with our core growth
of 15% in the fourth quarter and 10% for fiscal year 2007, as compared with the
same periods in 2006. During the past year, we have made substantial
investments in the Company which have begun to pay-off in terms of recent
top-line growth, particularly in the Water Purification and Endoscope
Reprocessing segments. We are focusing our efforts on realizing improvements in
profitability related to these investments over the next couple of years.
Jones continued, Our strategy is focused on enhancing our six existing
segments by adding proprietary product offerings, both through acquisitions and

internal
development, and by expanding our direct sales and service channels through
which to best address the needs of our customer base.

In line with its
strategy to make synergistic acquisitions and add to existing growth platforms,
the Company completed two acquisitions (GE
Water & Process Technologies dialysis water business and Twist 2 It
Inc.) during the fiscal year and three acquisitions (Dialysis Services, Inc.,
Verimetrix, LLC and Strong Dental Products, Inc.) during the past three months.
These transactions have added several important proprietary branded products to
its water purification and filtration, endoscope reprocessing and healthcare
disposables (previously referred to as dental) product lines.

The Company further reported that its balance sheet at July 31, 2007
included current assets of $76,731,000, including cash of $15,860,000, a
current ratio of 2.1:1, a ratio of funded debt to equity of .37:1, debt of
$57,000,000 and stockholders equity of $155,070,000.

Cantel Medical
Corp. is a leading provider of infection prevention and control products in the
healthcare market. Our products include specialized medical device reprocessing
systems for renal dialysis and endoscopy, dialysate concentrates and other
dialysis supplies, disposable infection control products primarily for the dental
industry, water purification equipment, sterilants, disinfectants and cleaners,
hollow fiber membrane filtration and separation products for medical and
non-medical applications, and specialty packaging for infectious and biological
specimens. We also provide technical maintenance for our products and offer
compliance training services for the transport of infectious and biological
specimens.

The Company will hold a
conference call to discuss the results for the fourth quarter ended July 31,
2007 on Tuesday, October 9, 2007 at 11:00 AM Eastern time. To participate in
the conference call, dial 1-877-407-8035 approximately 5 to 10 minutes before
the beginning of the call. If you are unable to participate, a digital replay
of the call will be available from Tuesday, October 9 at 2:00 PM through
midnight on October 10, by dialing 1-877-660-6853 and using passcode #286 and
conference ID #257825. The call will be simultaneously broadcast live over the
Internet on vcall.com at http://www.vcall.com/IC/CEPage.asp?ID=121882. A replay of the webcast will be available on
Vcall for 30 days.

For further information, visit the Cantel website at www.cantelmedical.com.

This
press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements involve a
number of risks and uncertainties, including, without limitation, the risks
detailed in Cantels filings and reports with the Securities and Exchange
Commission. Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or anticipated.